First Turn Management LLC Lowers Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

First Turn Management LLC decreased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 26.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 703,398 shares of the company's stock after selling 255,256 shares during the period. Mirum Pharmaceuticals comprises 3.9% of First Turn Management LLC's portfolio, making the stock its 5th largest holding. First Turn Management LLC owned about 1.49% of Mirum Pharmaceuticals worth $24,049,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MIRM. Quest Partners LLC increased its holdings in Mirum Pharmaceuticals by 7,513.3% during the second quarter. Quest Partners LLC now owns 1,142 shares of the company's stock valued at $39,000 after buying an additional 1,127 shares during the last quarter. StepStone Group LP purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at approximately $135,000. NEOS Investment Management LLC purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at approximately $220,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Mirum Pharmaceuticals by 66.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 8,952 shares of the company's stock worth $225,000 after purchasing an additional 3,558 shares in the last quarter. Finally, Arizona State Retirement System increased its stake in shares of Mirum Pharmaceuticals by 10.6% in the second quarter. Arizona State Retirement System now owns 9,210 shares of the company's stock worth $315,000 after purchasing an additional 883 shares in the last quarter.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, insider Pamela Vig sold 30,559 shares of the business's stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $34.00, for a total value of $1,039,006.00. Following the completion of the sale, the insider now directly owns 27,406 shares of the company's stock, valued at approximately $931,804. The transaction was disclosed in a filing with the SEC, which is available through this link. 22.87% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Stock Performance

MIRM stock opened at $41.13 on Friday. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $45.23. The company has a current ratio of 3.28, a quick ratio of 3.09 and a debt-to-equity ratio of 1.34. The company has a fifty day simple moving average of $40.46 and a two-hundred day simple moving average of $31.57.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.05). Mirum Pharmaceuticals had a negative return on equity of 43.47% and a negative net margin of 40.34%. The firm had revenue of $77.90 million for the quarter, compared to analysts' expectations of $75.03 million. During the same period in the prior year, the firm posted ($0.92) earnings per share. Mirum Pharmaceuticals's revenue for the quarter was up 107.7% on a year-over-year basis. Research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on MIRM. JMP Securities increased their price objective on shares of Mirum Pharmaceuticals from $66.00 to $68.00 and gave the stock a "market outperform" rating in a research note on Tuesday, June 18th. Evercore ISI increased their price objective on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an "outperform" rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. increased their price objective on shares of Mirum Pharmaceuticals from $31.00 to $39.00 and gave the stock an "overweight" rating in a research note on Tuesday, June 18th. Citigroup increased their price objective on shares of Mirum Pharmaceuticals from $38.00 to $64.00 and gave the stock a "buy" rating in a research note on Tuesday, June 18th. Finally, Morgan Stanley increased their price objective on shares of Mirum Pharmaceuticals from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Tuesday, June 18th. Ten research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Mirum Pharmaceuticals has an average rating of "Buy" and a consensus target price of $56.27.

Check Out Our Latest Stock Report on Mirum Pharmaceuticals

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Featured Articles

• Five stocks we like better than Mirum Pharmaceuticals
• What Are Dividend Champions? How to Invest in the Champions
• 3 Leveraged ETFs to Multiply Returns
• Insider Trading - What You Need to Know
• A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
• How Investors Can Identify and Successfully Trade Gap-Down Stocks
• Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ You won’t believe what this ex-Wall Street insider discovered about the election (From Banyan Hill Publishing) (Ad)

Should you invest $1,000 in Mirum Pharmaceuticals right now?

Before you consider Mirum Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mirum Pharmaceuticals wasn't on the list.

While Mirum Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here